Kenvue’s High-Yield Dividend Potential Amid Market Slump
Kenvue, the consumer health products spin-off from Johnson & Johnson, has seen its shares decline over 20% this year amid controversies surrounding its flagship products like Tylenol. The selloff has pushed its dividend yield above 5%, creating a potential value opportunity for investors.
The company, which houses iconic brands such as Band-Aid and Listerine, became an independent publicly traded entity in 2023 after J&J's IPO and subsequent separation. Market skepticism appears overdone given Kenvue's entrenched market position in self-care and skin health segments.
Analysts anticipate a rebound by 2026 as near-term headwinds subside. The current valuation disconnect presents a compelling entry point for dividend-focused portfolios, with the stock's depressed price amplifying its yield attractiveness.
